Hereditary Parkinsonism: Parkinson disease look-alikes - An algorithm for clinicians to "PARK" genes and beyond

Movement Disorders

Volumn 24, Issue 14, 2009, Pages 2042-2058

  Klein, Christine ^a,b   Schneider, Susanne A ^a,c   Lang, Anthony E ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Classification; Dystonia; Genetics; PARK; Parkinson

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE 7B; BETA GLUCOSIDASE; F BOX PROTEIN; F BOX PROTEIN 7; FERRITIN; FERRITIN LIGHT CHAIN 1; FRAGILE X MENTAL RETARDATION PROTEIN; GLUCOSYLCERAMIDASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PANTOTHENATE KINASE 2; PARKIN; PARKIN 2; PARKIN 6; PARKIN 7; PRION PROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR; TAU PROTEIN; UNCLASSIFIED DRUG;

BRAIN DISEASE; CHOREA-ACANTHOCYTOSIS; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINE RESPONSIVE DYSTONIA; DYSTONIA; DYSTONIA PARKINSONISM; ENVIRONMENTAL FACTOR; FRAGILE X SYNDROME; GAUCHER DISEASE; GENE MUTATION; HEREDITY; HUMAN; HUNTINGTON CHOREA; MITOCHONDRIAL GENE; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; ONSET AGE; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PARKINSON DISEASE; PARKINSONISM; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SPINOCEREBELLAR DEGENERATION; TRINUCLEOTIDE REPEAT; WILSON DISEASE;

ALGORITHMS; ENVIRONMENT; HETEROZYGOTE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; NEURODEGENERATIVE DISEASES; ONCOGENE PROTEINS; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 70450194705     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22675     Document Type: Review

References (186)

1. Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution. Multiple clues to a complex disorder. Neurology 2007;69:2093-2104.
2. Klein C, Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 2007;20:453-464. (Pubitemid 47051994)
3. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007;28:641-653.
4. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006;60:389-398.
5. Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol 2007;17:331-337. (Pubitemid 46880329)
6. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449-458.
7. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
8. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005;58:411-422.
9. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619-1622. (Pubitemid 38608210)
10. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005;20:1264-1271.
11. Di Fonzo A, Chien HF, Socal M, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007;68:1557-1562. (Pubitemid 46717978)
12. Paisan-Ruiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 2005;65:696-700. (Pubitemid 41285847)
13. Marras C, Klein C, Wakutani Y, et al. Lessons from a family multiple genetic aberrations assiciated with classical parkinsonism. Neurobiology [Epub ahead of print].
14. Reid AH, McCall S, Henry JM, Taubenberger JK. Experimenting on the past: the enigma of von Economo's encephalitis lethargica. J Neuropathol Exp Neurol 2001;60:663-670.
15. Steele JC. Parkinsonism-dementia complex of Guam. Mov Disord 2005;20(Suppl 12):S99-S107.
16. Morris HR, Steele JC, Crook R, et al. Genome-wide analysis of the parkinsonism-dementia complex of Guam. Arch Neurol 2004;61:1889-1897. (Pubitemid 39612949)
17. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
18. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5: 355-363.
19. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-1220.
20. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-1567.
21. Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, Lees A. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord 2001; 16:1007-1013. (Pubitemid 36041212)
22. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009;65:19-23.
23. Evidente VG, Lyons MK, Wheeler M, et al. First case of X-linked dystonia-parkinsonism ("Lubag") to demonstrate a response to bilateral pallidal stimulation. Mov Disord 2007;22:1790-1793. (Pubitemid 47597604)
24. Surtees R, Clayton P. Infantile parkinsonism-dystonia: tyrosine hydroxylase deficiency. Mov Disord 1998;13:350. (Pubitemid 28127815)
25. McKeon A, Ozelius LJ, Hardiman O, Greenway MJ, Pittock SJ. Heterogeneity of presentation and outcome in the Irish rapid-onset dystonia-Parkinsonism kindred. Mov Disord 2007;22:1325-1327. (Pubitemid 47325043)
26. Lee JY, Gollamudi S, Ozelius LJ, Kim JY, Jeon BS. ATP1A3 mutation in the first asian case of rapid-onset dystonia-parkinsonism. Mov Disord 2007;22:1808-1809. (Pubitemid 47597609)
27. Shan DE, Liu RS, Sun CM, Lee SJ, Liao KK, Soong BW. Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: clinical implications. Mov Disord 2004;19:1357-1360.
28. Lu CS, Wu Chou YH, Yen TC, Tsai CH, Chen RS, Chang HC. Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2. Mov Disord 2002;17:1046-1051. (Pubitemid 36041013)
29. Subramony SH, Currier RD. Intrafamilial variability in Machado-Joseph disease. Mov Disord 1996;11:741-743.
30. Khan NL, Giunti P, Sweeney MG, et al. Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov Disord 2005;20:1115-1119. (Pubitemid 41632197)
31. Molinuevo JL, Marti MJ, Blesa R, Tolosa E. Pure akinesia: an unusual phenotype of Hallervorden-Spatz syndrome. Mov Disord 2003;18:1351-1353. (Pubitemid 38263323)
32. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007;22:2018-2030; quiz 2140.
33. Bardien S, Abrahams F, Soodyall H, et al. A South African mixed ancestry family with Huntington disease-like 2: clinical and genetic features. Mov Disord 2007;22:2083-2089.
34. Fasano A, Colosimo C, Miyajima H, Tonali PA, Re TJ, Bentivoglio AR. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov Disord 2008;23:751-755.
35. Roze E, Paschke E, Lopez N, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005;20:1366-1369. (Pubitemid 41645916)
36. Evans AH, Costa DC, Gacinovic S, et al. L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: in vivo dopamine transporter and D2 receptor findings. Mov Disord 2004;19:1232-1236. (Pubitemid 39429968)
37. Haugarvoll K, Rademakers R, Kachergus JM, et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008;70(16 Part 2):1456-1460.
38. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7: 583-590.
39. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003;54:176-185.
40. Abou-Sleiman PM, Muqit MM, McDonald NQ, et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 2006;60:414-419.
41. Steinlechner S, Stahlberg J, Volkel B, et al. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J Neurol Neurosurg Psychiatry 2007;78:532-535. (Pubitemid 46662908)
42. Criscuolo C, Volpe G, De Rosa A, et al. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov Disord 2006;21:1265-1267. (Pubitemid 44336626)
43. Vekrellis K, Rideout HJ, Stefanis L. Neurobiology of alpha- Synuclein. Mol Neurobiol 2004;30:1-22.
44. Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007;68:916-922. (Pubitemid 46568503)
45. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40:767-775. (Pubitemid 26415189)
46. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184-1191. (Pubitemid 44470365)
47. Lees AJ, Singleton AB. Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology 2007;68:1553-1554.
48. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009;65:19-23.
49. Khateeb S, Flusser H, Ofir R, et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 2006;79:942-948. (Pubitemid 44763408)
50. Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003;33:85-89. (Pubitemid 36068688)
51. Grimes DA, Han F, Panisset M, et al. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord 2006;21:906-909. (Pubitemid 44184588)
52. Wellenbrock C, Hedrich K, Schafer N, et al. NR4A2 mutations are rare among European patients with familial Parkinson's disease. Ann Neurol 2003;54:415. (Pubitemid 37072047)
53. Zimprich A, Asmus F, Leitner P, et al. Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease. Neurogenetics 2003;4:219-220. (Pubitemid 37122224)
54. Hering R, Petrovic S, Mietz EM, et al. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology 2004;62:1231-1232. (Pubitemid 38456532)
55. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol 1998;78:1-10.
56. Camargos S, Scholz S, Simon-Sanchez J, et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 2008;7:207-215.
57. Makino S, Kaji R, Ando S, et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia- parkinsonism. Am J Hum Genet 2007;80:393-406. (Pubitemid 46310972)
58. Lee LV, Kupke KG, Caballar-Gonzaga F, Hebron-Ortiz M, Muller U. The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines. Medicine (Baltimore) 1991;70:179-187.
59. Müller U, Steinberger D, Nemeth A. Clinical and molecular genetics of primary dystonias. Neurogenetics 1998;1:165-177. (Pubitemid 128684237)
60. Evidente VG, Advincula J, Esteban R, et al. Phenomenology of "Lubag" or X-linked dystonia-parkinsonism. Mov Disord 2002; 17:1271-1277.
61. Gwinn-Hardy K. Genetics of parkinsonism. Mov Disord 2002;17:645-656.
62. Evidente VG, Nolte D, Niemann S, et al. Phenotypic and molecular analyses of X-linked dystonia-parkinsonism ("lubag") in women. Arch Neurol 2004;61:1956-1959.
63. Tackenberg B, Metz A, Unger M, et al. Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3). Mov Disord 2007;22:900-902. (Pubitemid 46800123)
64. Eidelberg D, Takikawa S, Wilhelmsen K, et al. Positron emission tomographic findings in Filipino X-linked dystonia-parkinsonism. Ann Neurol 1993;34:185-191. (Pubitemid 23223046)
65. Waters CH, Faust PL, Powers J, et al. Neuropathology of lubag (x-linked dystonia parkinsonism). Mov Disord 1993;8:387-390. (Pubitemid 23212558)
66. Nar H, Huber R, Auerbach G, et al. Active site topology and reaction mechanism of GTP cyclohydrolase I. Proc Natl Acad Sci USA 1995;92:12120-12125. (Pubitemid 26014023)
67. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976;14:215-233.
68. Brautigam C, Steenbergen-Spanjers GC, Hoffmann GF, et al. Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin Chem 1999;45: 2073-2078.
69. de Rijk-van Andel J, Gabreels F, Geurtz G, et al. L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency. Neurology 2000;55:1926-1928. (Pubitemid 32103983)
70. Lopez-Laso E, Camino R, Mateos ME, et al. Dopa-responsive infantile hypokinetic rigid syndrome due to dominant guanosine triphosphate cyclohydrolase 1 deficiency. J Neurol Sci 2007;256:90-93. (Pubitemid 46560628)
71. Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, Fung VS, Earl J, Wilcken B. Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Mov Disord 2002;17:354-359. (Pubitemid 36041305)
72. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 1990;40:66-69. (Pubitemid 20032895)
73. Bandmann O, Daniel S, Marsden CD, Wood NW, Harding AE. The GTP-cyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study. J Neurol Sci 1996;141:27-32. (Pubitemid 26297725)
74. Hertz JM, Ostergaard K, Juncker I, et al. Low frequency of Parkin, tyrosine hydroxylase, and GTP cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease. Eur J Neurol 2006;13:385-390.
75. Paviour DC, Surtees RA, Lees AJ. Diagnostic considerations in juvenile parkinsonism. Mov Disord 2004;19:123-135.
76. Nutt JG, Nygaard TG. Response to levodopa treatment in dopa-responsive dystonia. Arch Neurol 2001;58:905-910. (Pubitemid 32537465)
77. Tassin J, Durr A, Bonnet AM, et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 2000;123 (Part 6):1112-1121.
78. Turjanski N, Bhatia K, Burn DJ, Sawle GV, Marsden CD, Brooks DJ. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology 1993;43:1563-1568.
79. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-1423. (Pubitemid 38035363)
80. Nagatsu T, Ichinose H. GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism. Neurochem Res 1996;21:245-250. (Pubitemid 26154452)
81. Hagenah JM, Hedrich K, Becker B, Pramstaller PP, Seidel G, Klein C. Distinguishing early-onset PD from dopa-responsive dystonia with transcranial sonography. Neurology 2006;66:1951-1952. (Pubitemid 44049840)
82. Grotzsch H, Pizzolato GP, Ghika J, et al. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology 2002;58:1839-1842. (Pubitemid 34663588)
83. Nygaard TG, Wooten GF. Dopa-responsive dystonia: some pieces of the puzzle are still missing. Neurology 1998;50:853-855.
84. de Carvalho Aguiar P, Sweadner KJ, Penniston JT, et al. Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 2004;43:169-175.
85. + interaction by distinct mechanisms. J Biol Chem 2006;281:18539-18548.
86. Brashear A, Dobyns WB, de Carvalho Aguiar P, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007;130 (Part 3):828-835. (Pubitemid 46410729)
87. Zaremba J, Mierzewska H, Lysiak Z, Kramer P, Ozelius LJ, Brashear A. Rapid-onset dystonia-parkinsonism: a fourth family consistent with linkage to chromosome 19q13. Mov Disord 2004;19:1506-1510. (Pubitemid 40104064)
88. Brashear A, DeLeon D, Bressman SB, Thyagarajan D, Farlow MR, Dobyns WB. Rapid-onset dystonia-parkinsonism in a second family. Neurology 1997;48:1066-1069.
89. Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia- parkinsonism. Neurology 1993;43:2596-2602.
90. Kamphuis DJ, Koelman H, Lees AJ, Tijssen MA. Sporadic rapid-onset dystonia-parkinsonism presenting as Parkinson's disease. Mov Disord 2006;21:118-119. (Pubitemid 43273766)
91. Taroni F, DiDonato S. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci 2004;5:641-655. (Pubitemid 39013595)
92. Orr H, Zoghbi H. Trinucleotide repeat disorders. Annu Rev Neurosci 2007;30:575-621.
93. Schols L, Kruger R, Amoiridis G, Przuntek H, Epplen JT, Riess O. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 1998;64:67-73. (Pubitemid 28156540)
94. Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000;55:800-805. (Pubitemid 30727719)
95. Lu CS, Chang HC, Kuo PC, et al. The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. Parkinsonism Relat Disord 2004;10:369-373. (Pubitemid 38942793)
96. Furtado S, Farrer M, Tsuboi Y, et al. SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. Neurology 2002;59:1625-1627. (Pubitemid 35387073)
97. Charles P, Camuzat A, Benammar N, et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology 2007;69:1970-1975.
98. Kim JM, Hong S, Kim GP, et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol 2007;64:1510-1518. (Pubitemid 47572675)
99. Lim SW, Zhao Y, Chua E, et al. Genetic analysis of SCA2, 3 and 17 in idiopathic Parkinson's disease. Neurosci Lett 2006;403:11-14. (Pubitemid 43963231)
100. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol 2001;58:296-299. (Pubitemid 32163168)
101. Giunti P, Sweeney MG, Harding AE. Detection of the Machado-Joseph disease/spinocerebellar ataxia three trinucleotide repeat expansion in families with autosomal dominant motor disorders, including the Drew family of Walworth. Brain 1995;118(Part 5):10771-11085
102. Tuite PJ, Rogaeva EA, St George-Hyslop PH, Lang AE. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995;38:684-687.
103. Yoritaka A, Nakagawa-Hattori Y, Hattori N, Kitahara A, Mizuno Y. A large Japanese family with Machado-Joseph disease: clinical and genetic analysis. Acta Neurol Scand 1999;99:241-244. (Pubitemid 29166843)
104. Yamada M, Sato T, Tsuji S, Takahashi H. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol 2008;115:71-86. (Pubitemid 350238668)
105. Wu YR, Lin HY, Chen CM, et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. Clin Genet 2004;65:209-214.
106. Wu YR, Fung HC, Lee-Chen GJ, et al. Analysis of polyglutamine- coding repeats in the TATA-binding protein in different neurodegenerative diseases. J Neural Transm 2005;112:539-546.
107. Schapira AH. Mitochondrial disease. Lancet 2006;368:70-82.
108. Muqit MM, Gandhi S, Wood NW. Mitochondria in Parkinson disease: back in fashion with a little help from genetics. Arch Neurol 2006;63:649-654.
109. Mancuso M, Filosto M, Bellan M, et al. POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness. Neurology 2004;62:316-318. (Pubitemid 38167151)
110. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004;364:875-882. (Pubitemid 39221065)
111. Davidzon G, Greene P, Mancuso M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 2006;59:859-862. (Pubitemid 43673164)
112. Thyagarajan D, Bressman S, Bruno C, et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol 2000;48:730-736. (Pubitemid 30823223)
113. Grasbon-Frodl EM, Kosel S, Sprinzl M, von Eitzen U, Mehraein P, Graeber MB. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. Neurogenetics 1999;2:121-127. (Pubitemid 29234440)
114. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-1977. (Pubitemid 39447138)
115. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67:908-910. (Pubitemid 44394221)
116. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81:70-73.
117. Eblan MJ, Walker JM, Sidransky E. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2005;352:728-731.
118. Sidransky E. Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet 2006;70:275-282. (Pubitemid 44323390)
119. Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003;61:99-101. (Pubitemid 36818755)
120. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008;65:1353-1357.
121. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41:937-940.
122. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6:652-662. (Pubitemid 46921058)
123. Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007;69:1270-1277. (Pubitemid 47429028)
124. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70:2277-2283.
125. Eblan MJ, Nguyen J, Ziegler SG, et al. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord 2006;21:282-283.
126. Sato C, Morgan A, Lang AE, et al. Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005;20:367-370. (Pubitemid 40613301)
127. Ziegler SG, Eblan MJ, Gutti U, et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007;91:195-200. (Pubitemid 46765177)
128. Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72:310-316.
129. Toft M, Pielsticker L, Ross OA, Aasly JO, Farrer MJ. Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006;66:415-417. (Pubitemid 43739947)
130. Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 2005;65:1460-1461. (Pubitemid 41552780)
131. Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-321. (Pubitemid 32846370)
132. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57:127-130. (Pubitemid 32634862)
133. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007;6:45-55. (Pubitemid 44880272)
134. Berry-Kravis E, Lewin F, Wuu J, et al. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol 2003;53:616-623. (Pubitemid 36529435)
135. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Mov Disord 2007;22:2018-2030.
136. Hall DA, Berry-Kravis E, Jacquemont S, et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005;65:299-301. (Pubitemid 41022379)
137. Ceravolo R, Antonini A, Volterrani D, et al. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. Neurology 2005;65:1971-1973. (Pubitemid 43970123)
138. Healy D, Bressman S, Dickson J, et al. Evidence for pre and postsynaptic nigrostriatal degeneration in the fragile X tremor ataxia syndrome. Mov Disord [Epub ahead of print].
139. Scaglione C, Ginestroni A, Vella A, et al. MRI and SPECT of midbrain and striatal degeneration in fragile X-associated tremor/ataxia syndrome. J Neurol 2008;255:144-146.
140. Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006;129(Part 1):243-255. (Pubitemid 43063775)
141. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
142. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-1364.
143. Jimenez-Escrig A, Rabano A, Guerrero C, et al. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur J Neurol 2004;11:663-669. (Pubitemid 39389667)
144. Takao M, Ghetti B, Hayakawa I, et al. A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol (Berl) 2002;104:155-170. (Pubitemid 36075374)
145. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920-924. (Pubitemid 44285947)
146. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-919. (Pubitemid 44285946)
147. Yasuda M, Nakamura Y, Kawamata T, Kaneyuki H, Maeda K, Komure O. Phenotypic heterogeneity within a new family with the MAPT p301s mutation. Ann Neurol 2005;58:920-928. (Pubitemid 41746882)
148. Kelley BJ, Haidar W, Boeve BF, et al. Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging 2009;30:739-751.
149. Bugiani O. The many ways to frontotemporal degeneration and beyond. Neurol Sci 2007;28:241-244. (Pubitemid 350055432)
150. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 2007;114:5-22.
151. Cruts M, Kumar-Singh S, Van Broeckhoven C. Progranulin mutations in ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Curr Alzheimer Res 2006;3:485-491. (Pubitemid 46066424)
152. Farrer MJ, Williams LN, Algom AA, et al. Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat Disord [Epub ahead of print].
153. Wider C, Melquist S, Hauf M, et al. Study of a Swiss doparesponsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. Neurology 2008;70(Part 2):1377-1383.
154. Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278:245-251.
155. Iida T, Doh-ura K, Kawashima T, Abe H, Iwaki T. An atypical case of sporadic Creutzfeldt-Jakob disease with Parkinson's disease. Neuropathology 2001;21:294-297. (Pubitemid 34130636)
156. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327-337. (Pubitemid 23351302)
157. Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992;55:692-696.
158. Johnson S. Is Parkinson's disease the heterozygote form of Wilson's disease: PD = 1/2 WD? Med Hypotheses 2001;56:171-173.
159. Sechi G, Antonio Cocco G, Errigo A, et al. Three sisters with very-late-onset major depression and parkinsonism. Parkinsonism Relat Disord 2007;13:122-125. (Pubitemid 46329514)
160. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349. (Pubitemid 32702423)
161. Pellecchia MT, Valente EM, Cif L, et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005;64:1810-1812. (Pubitemid 40695829)
162. Klopstock T, Elstner M, Lucking CB, et al. Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease. Neurosci Lett 2005;379:195-198. (Pubitemid 40544533)
163. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-354. (Pubitemid 32702424)
164. Burn J, Chinnery PF. Neuroferritinopathy. Semin Pediatr Neurol 2006;13:176-181.
165. Shojaee S, Sina F, Banihosseini SS, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet 2008;82:1375-1384.
166. Di Fonzo A, Dekker MC, Montagna P, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009;72:240-245.
167. Rampoldi L, Dobson-Stone C, Rubio JP, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 2001;28:119-120. (Pubitemid 32538051)
168. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991;114(Part 1A):13-49.
169. Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology 1985;35:366-370. (Pubitemid 15100677)
170. Rampoldi L, Danek A, Monaco AP. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med 2002;80:475-491. (Pubitemid 34983912)
171. Bostantjopoulou S, Katsarou Z, Kazis A, Vadikolia C. Neuroacanthocytosis presenting as parkinsonism. Mov Disord 2000;15:1271-1273.
172. Geser F, Tolnay M, Jung H. The neuropathology of McLeod Syndrome. In Walker RH, Saiki S, Danek A, editors. Neuroacanthocytosis II. Berlin: Springer; 2008. p 197-204.
173. Group HsDS. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group. Cell 1993;72:817-818.
174. Walker F. Huntington's disease. Lancet 2007;369:218-228.
175. Nance MA, Mathias-Hagen V, Breningstall G, Wick MJ, McGlennen RC. Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Neurology 1999; 52:392-394. (Pubitemid 29059072)
176. Rasmussen A, Macias R, Yescas P, Ochoa A, Davila G, Alonso E. Huntington disease in children: genotype-phenotype correlation. Neuropediatrics 2000;31:190-194. (Pubitemid 30775248)
177. Wojaczynska-Stanek K, Adamek D, Marszal E, Hoffman- Zacharska D. Huntington disease in a 9-year-old boy: clinical course and neuropathologic examination. J Child Neurol 2006;21:1068-1073. (Pubitemid 46128361)
178. Nance MA, Myers RH. Juvenile onset Huntington's disease - clinical and research perspectives. Ment Retard Dev Disabil Res Rev 2001;7:153-157. (Pubitemid 32843805)
179. van Dijk J, van der Velde E, Roos R, Bruyn G. Juvenile Huntignton disease. Hum Genet 1986;73:235-239.
180. Schapiro M, Cecil KM, Doescher J, Kiefer AM, Jones BV. MR imaging and spectroscopy in juvenile Huntington disease. Pediatr Radiol 2004;34:640-643. (Pubitemid 39162250)
181. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 1990;27:357-365. (Pubitemid 20132050)
182. Squitieri F, Berardelli A, Nargi E, et al. Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis. Clin Genet 2000;58:50-56. (Pubitemid 30468429)
183. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998;65:577-579.
184. Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000;68:238-241. (Pubitemid 30245854)
185. Schneider SA, Walker RH, Bhatia KP. The Huntington's disease- like syndromes: what to consider in patients with a negative Huntington's disease gene test. Nat Clin Pract Neurol 2007;3:517-525.
186. Sévin M, Lesca G, Baumann N, et al. The adult form of Niemann- Pick disease type C. Brain 2007;130:120-133. (Pubitemid 46026228)